Navidea Biopharmaceuticals Inc. (AMEX:NAVB) does about 147.24K shares in volume on a normal day but saw 240837 shares change hands in Friday trading. The company now has a market cap of 9.34M USD. Its current market price is $0.29, marking an increase of 1.72% compared to the previous close of $0.29. The 52 week high reached by this stock is $1.24 whilst the lowest price level in 52 weeks is $0.16. The script in recent trading has seen the stock touch a high of $0.33 and a low of $0.27.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Navidea Biopharmaceuticals Inc. (NAVB) has a 20-day trading average at $0.2944 and the current price is -76.61% off the 52-week high compared with 81.25% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.2731 and its 200-day simple moving average is $0.4365. If we look at the stock’s price movements over the week, volatility stands at 15.29%, which decreases to 11.83% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 50.44 to suggest the stock is neutral.
1 analysts observing the Navidea Biopharmaceuticals Inc. (NAVB) stock have set the 12-month price targets for the company’s shares at between $8.00 and $8.00. The median price target is 96.38% away from the current levels at $8.00.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 13, 2013 when Aegis Capital reiterated the stock to “Hold” and issued a price target of between $3 and $2. Burrill Institutional Research initiated its price target at $5.
The current price level is -1.41%, 6.48%, and -34.12% away from its SMA20, SMA50, and SMA200 respectively, with the NAVB price moving below the 50-day SMA on February 17. Navidea Biopharmaceuticals Inc. (NAVB) stock is down -10.36% over the week and 7.37% over the past month. Its price is 38.10% year-to-date and -68.07% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2021, with the company’s earnings per share (EPS) of -$0.08 above consensus estimates by $0.03. The company’s next earnings report is expected on 05/09/2023. In addition, estimates put the company’s current quarterly revenue at an average of $50k.
Its 12-month price target is $8.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $8.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $8.00.
Outstanding shares total 30.73M with insiders holding 31.19% of the shares and institutional holders owning 4.69% of the company’s common stock. The company has a return on equity of 579.40%. The beta has a value of 1.53. Price to sales ratio is 93.38.
